Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An In Vivo Confocal Microscopy Study

Table 2

Clinical data comparison between control (group 1) and antiglaucoma therapy groups (groups 2, 3, 4, and 5).

	Group 1 (control)	Group 2 (Bb)	Group 3 (Aa)	Group 4 (Pg)	Group 5 (Ct)	P
OSDIQ	8.1 ± 4.7	12.0 ± 10.8	18.6 ± 18.8	17.5 ± 15.6	31.4 ± 16.5	0.000
Schirmer’s I test	11.9 ± 4.1	7.7 ± 6.4	9.6 ± 6.2	6.2 ± 3.8	6.2 ± 4.8	0.002
Break-up time	11 ± 2.5	4.7 ± 2.7	5.0 ± 3	3.8 ± 2.4	3.3 ± 1.8	0.000

Bb: beta-blockers group; Aa: alpha adrenergic agonists group; Pg: prostaglandin group; Ct: combination therapy group; OSDIQ: Ocular Surface Disease Index Questionnaire.
Control group showed better clinical results than antiglaucoma therapy groups (confidence interval: 95%).
All data are expressed as mean ± standard deviation. P is by analysis of variance.